Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand

Q: What type of study is this?

This is a Quantitative Study study (also classified as: Cohort Study).

Siriwat Akapirat; Elisavet Serti; Punnee Pitisutthithum; Sorachai Nitayaphan; Suwat Chariyalertsak; Chirapa Eamsila; Pornchanok Panjapornsuk; Anocha Kleebmontha; Somsak Chantakulkij; Bhubate Tongchanakarn; Hathairat Savadsuk; Jittima Dhitavat; Sanjay Gurunathan; Faruk Sinangil; Trevor A. Crowell; Nelson L. Michael; Merlin L. Robb; Sandhya Vasan; Robert J. O’Connell; Punnee Pitisuttithum; Jittima Dhitavat Benjaluck Phonrat; Supat Chamnanchanunt; Arom Pitisuttithum; Kessuda Khowsroy; Sorachai Nitayaphan; Narongrid Sirisopana; Chirapa Eamsila; Wanlaya Lapwech; Prapaporn Savaraj; Siriluck Teerachia; Suwat Chariyalertsak; Natthapol Kosashunhanan; Nuntisa Chotirosniramit; Oranitcha Kaewthip; Taweewat Supindham; Wathee Sithi; Patcharaphan Sugandhavesa; Kittipong Rungruengthanakit; Kanlaya Wongworapat; Piyathida Sroysuwan; Boonlure Pruenglampoo; Praphan Phanuphak; Nittaya Phanuphak; Thep Chalermchai; James L. K. Fletcher; Eugène Kroon; Nipat Teeratakulpisarn; Nitiya Chomchey; Putthachard Saengtawan; Jaranit Kaewkungwal; Pawinee Jarujareet; Robert J. O’Connell; Nicos Karasavvas; Alexandra Schuetz; Kirsten Smith; Siriwat Akapirat; Chitraporn Karnasuta; Sirinan Madnote; Surawach Rittiroongrad; Jiraporn Puangkaew; Somsak Chantakulkij; Bessara Nuntapinit; Phiromrat Rakyat; Tanyaporn Wansom; Anant Phramtong; Rapee Trichavaroj; Bhubate Tongchanakarn Hathairat Savadsuk; Kittimasak Hunprasert Yuwadee Puangngern; Surat Jongrakthaitae; Weerawan Chuenarom; Nongluck Sangnoi; Nampueng Churikanont; Pornsuk Visudhiphan Saowanit Getchalarat; Sandhya Vasan; Nelson L. Michael; Jintanat Ananworanich; Jerome H. Kim; Merlin L. Robb; Leigh Anne Eller; Chiaka Nwoga; Elizabeth Heger; Jean‐Louis Excler; Charla Andrews; Faruk Sinangil; Carter Lee; Donald Francis; James Tartaglia; Sanjay Phogat

doi:10.1093/ofid/ofaf578

September 16, 2025Open Forum Infectious DiseasesOpen Access

Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand

View Full Paper

Ask AI

Bookmark

Share

Key Points

Selecting appropriate HIV tests can nearly eliminate vaccine-induced seroreactivity in RV306 trials.
Vaccine-induced seroreactivity ranged from 0-32.5% across different HIV diagnostics and algorithms used.
The study shows that avoiding certain tests can minimize VISR, impacting diagnostic accuracy for HIV.
Evaluating vaccine-induced seroreactivity is crucial for optimizing HIV vaccine testing protocols.

Implication

This evaluation identifies significant variations in VISR among HIV diagnostic tests, suggesting improvements in testing algorithms.

Abstract

Vaccine-induced seroreactivity (VISR) was evaluated in RV306 and was shown to vary markedly (0-32.5%) among six HIV diagnostic tests and 84 algorithms. Our data show that selecting the SD Bioline HIV-1/2 assay and algorithms which exclude the ImmunoComb®II Bispot and Alere™ Determine HIV-1/2 assays would almost eliminate VISR in RV306.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Akapirat et al. (2025) studied this question.

synapsesocial.com/papers/68d46aa631b076d99fa67609 https://doi.org/10.1093/ofid/ofaf578

View Full Paper

Ask AI

Bookmark

Share

Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand

Key Points

Implication

Abstract

Discussion

Cite This Study

Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading